On course for a cancer vaccine

Tumor endothelial marker 8 enhances tumor immunity in conjunction with immunization against differentiation Ag.

Cytotherapy·2008

Tumor endothelial marker 8 enhances tumor immunity in conjunction with immnization against differentiation Ag.

Cytotherapy·2007

In vitro expansion of Ag-specific T cells by HLA-A*0201-transfected K562 cells for immune monitoring.

Cytotherapy·2006

Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center.

Vaccine·2005

Evaluation of Elispot assays: influence of method and operator on variability of results.

Journal of immunological methods·2004

Alternative roles for interferon-gamma in the immune response to DNA vaccines encoding related melanosomal antigens.

Cancer immunity·2003

Efficacy and safety of upadacitinib in adults and adolescents for treatment of non-segmental vitiligo (Viti-Up): results of two phase 3 randomised controlled studies.

Lancet (London, England)·2026

Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial.

Lancet (London, England)·2026

Switch to once-weekly, single-tablet islatravir-lenacapavir from daily standard of care for HIV-1 (ISLEND-2): a multicentre, randomised, open-label, active-controlled, phase 3 non-inferiority trial.

Lancet (London, England)·2026

[177Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial.

Lancet (London, England)·2026

Analysis of real-world clinical outcomes of perioperative chemotherapy compared to preoperative chemoradiotherapy in esophagogastric adenocarcinoma.

Cancer·2026

RETRACTION: USP44 Suppresses Proliferation and Enhances Apoptosis in Colorectal Cancer Cells by Inactivating the Wnt/β-catenin Pathway via Axin1 Deubiquitination.

Cell biology international·2026

First-line sugemalimab plus chemotherapy for metastatic non-small-cell lung cancer: an updated cost-effectiveness analysis based on 4-year survival data.

Expert review of pharmacoeconomics & outcomes research·2026

Survival Benefit of ARSI Therapy in Japanese mCSPC: A Systematic Review and Meta-Analysis.

International journal of urology : official journal of the Japanese Urological Association·2026

Patterns of radiological response to procarbazine and CCNU polychemotherapy in patients with oligodendroglioma.

Neuro-oncology advances·2026

Durable Complete Response Following Nivolumab Discontinuation in Human Papillomavirus (HPV)-Positive Oropharyngeal Carcinoma Complicated by Bullous Pemphigoid: A Case Report.

Cureus·2026

Related Experiment Videos

On course for a cancer vaccine

Related Concept Videos

Tumor endothelial marker 8 enhances tumor immunity in conjunction with immunization against differentiation Ag.

Tumor endothelial marker 8 enhances tumor immunity in conjunction with immnization against differentiation Ag.

In vitro expansion of Ag-specific T cells by HLA-A*0201-transfected K562 cells for immune monitoring.

Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center.

Evaluation of Elispot assays: influence of method and operator on variability of results.

Alternative roles for interferon-gamma in the immune response to DNA vaccines encoding related melanosomal antigens.

Efficacy and safety of upadacitinib in adults and adolescents for treatment of non-segmental vitiligo (Viti-Up): results of two phase 3 randomised controlled studies.

Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial.

Switch to once-weekly, single-tablet islatravir-lenacapavir from daily standard of care for HIV-1 (ISLEND-2): a multicentre, randomised, open-label, active-controlled, phase 3 non-inferiority trial.

[177Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial.

Analysis of real-world clinical outcomes of perioperative chemotherapy compared to preoperative chemoradiotherapy in esophagogastric adenocarcinoma.

RETRACTION: USP44 Suppresses Proliferation and Enhances Apoptosis in Colorectal Cancer Cells by Inactivating the Wnt/β-catenin Pathway via Axin1 Deubiquitination.

First-line sugemalimab plus chemotherapy for metastatic non-small-cell lung cancer: an updated cost-effectiveness analysis based on 4-year survival data.

Survival Benefit of ARSI Therapy in Japanese mCSPC: A Systematic Review and Meta-Analysis.

Patterns of radiological response to procarbazine and CCNU polychemotherapy in patients with oligodendroglioma.

Durable Complete Response Following Nivolumab Discontinuation in Human Papillomavirus (HPV)-Positive Oropharyngeal Carcinoma Complicated by Bullous Pemphigoid: A Case Report.

Related Experiment Videos

On course for a cancer vaccine

Related Concept Videos

Related Articles